Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Oncoinvent ASA ( (BRRGD) ).
Oncoinvent has enrolled the first patient at one of four newly activated clinical sites in its ongoing randomized Phase 2 trial of Radspherin in patients with peritoneal carcinomatosis from ovarian cancer, expanding the study’s footprint to a total of 11 sites across Norway, Spain, Belgium, the UK, the US and Italy. The trial compares progression-free survival in patients receiving Radspherin after complete surgical resection and pre-operative chemotherapy versus standard treatment without Radspherin, building on earlier Phase 1/2a data that showed the therapy was well tolerated with no dose-limiting toxicities at the recommended dose, a development that underscores the company’s progress in advancing its lead asset and strengthening its position in the emerging radiopharmaceutical oncology market.
More about Oncoinvent ASA
Oncoinvent ASA is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for solid cancers. Its lead product candidate, Radspherin, is an alpha-emitting radium-224 based microparticle therapy designed for local treatment of micro-metastatic disease in body cavities following surgery, particularly peritoneal carcinomatosis from ovarian and colorectal cancer. The company runs a state-of-the-art manufacturing facility in Oslo to supply its clinical programs in the US and Europe and is listed on the Oslo Stock Exchange.
Average Trading Volume: 15,721
Current Market Cap: NOK188.1M
Learn more about BRRGD stock on TipRanks’ Stock Analysis page.